VSL#3

VSL Pharmaceuticals is a specialized healthcare company focused on the commercialization of high-potency probiotic medical foods under the VSL#3 brand. The company's primary product, VSL#3, consists of a proprietary blend of eight strains of live lactic acid bacteria and bifidobacteria designed for the dietary management of chronic gastrointestinal conditions. Specifically, the product is marketed for patients with ulcerative colitis, irritable bowel syndrome (IBS), and pouchitis. VSL Pharmaceuticals has been involved in extensive litigation regarding the ownership and formulation of its flagship product, leading to a legal distinction between the current VSL#3 and the original De Simone Formulation. The company operates as a subsidiary of the Italian firm Actial Farmaceutica and maintains a significant presence in the global medical food market.